MedTrace Logo

Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

NCT04778839 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2025-08-06

No results posted yet for this study

Summary

A Phase I Study of Dose Escalation and Dose Expansion To Evaluate the Safety、Tolerability、Pharmacokinetics and Preliminary Efficacy of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumor.

Conditions

Interventions

DRUG

Paclitaxel Micelles for Injection

Paclitaxel Micelles for Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.

DRUG

Paclitaxel injection

Paclitaxel Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.

Sponsors & Collaborators

  • Hangzhou Dihua Biotechnology Co., LTD.

    collaborator UNKNOWN

  • First Affiliated Hospital of Zhejiang University

    lead OTHER

Principal Investigators

  • jian liu, master · The First Affiliated Hospital,ZheJiang Univercity

  • xiaochen zhang, docter · The First Affiliated Hospital,ZheJiang Univercity

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-04
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • China

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04778839 on ClinicalTrials.gov